JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v9i9.12271ArticleA Seven-Year Surveillance of Epidemiological Trends of Serratia marcescens with Different Infection Types in a Tertiary Hospital in Chinahttps://artdesignp.com/journal/JCNR/9/9/10.26689/jcnr.v9i9.12271ZhuQingtang,LiuBo,WuJie,ChenCaiyun2025992025-10-16Objective: To explore the trend of detection and antimicrobial resistance of Serratia marcescens with different infection types for 7 consecutive years, to provide a reference for future studies for the control of S. marcescens infections and a rational selection of antibiotics. Methods: S. marcescens isolates were collected from 2014 to 2020, and the trend of detection and antimicrobial resistance were analyzed according to different types of infection. Results: For 7 consecutive years, the data showed that patients with S. marcescens infections were mainly from the intensive care unit (ICU) (384 isolates, 40.98%), and the isolates recovered were mainly from sputum samples (743 isolates, 79.30%). The number of isolated strains increased every year, and the average rate of detection ranged from 0.60% to 0.80%. The detection rate of S. marcescens with hospital-acquired infections (HAI) showed a downward trend and that of S. marcescens with colonization showed an upward trend. The detection rate of multidrug-resistant S. marcescens fluctuated between 8.33%–16.89%. The resistance rate of S. marcescens to piperacillin was 17.0%–29.06% and the resistance rate to piperacillin tazobactam was 2.95%–13.13%. For cephalosporin antibiotics, the resistance rates of S. marcescens to cefuroxime and cefazolin were > 99% and the resistance rates to ceftazidime and cefepime were < 13%. The resistance rate of S. marcescens to aminoglycoside antibiotics, especially amikacin, was the lowest. The resistance rate of S. marcescens with community-acquired infections (CAI) to carbapenems was higher than that with HAI and colonization. Conclusion: The different infection types of S. marcescens have different detection and epidemic trends. In addition, resistance to carbapenems is different across the strains.

Hejazi A, Falkiner F. 1997, Serratia Marcescens. Journal of Medical Microbiology, 46: 903–912.

Kim E, Park W, Yoon J, et al. 2020, Outbreak Investigation of Serratia Marcescens Neurosurgical Site Infections Associated With Contaminated Shaving Razors. Antimicrobial Resistance and Infection Control, 9(1): 64.

Redondo-Bravo L, Gutierrez-Gonzalez E, San Juan-Sanz I, et al. 2019, Serratia Marcescens Outbreak in a Neonatology Unit of a Spanish Tertiary Hospital: Risk Factors and Control Measures. American Journal of Infection Control, 47(3): 271–279.

European Centre for Disease Prevention and Control. 2018, Healthcare-Associated Infections Acquired in Intensive Care Units. ECDC Annual Epidemiological Report for 2016, Stockholm, Sweden.

Gupta N, Hocevar S, Moulton-Meissner H, et al. 2014, Outbreak of Serratia Marcescens Bloodstream Infections in Patients Receiving Parenteral Nutrition Prepared by a Compounding Pharmacy. Clinical Infectious Diseases, 59(1): 1–8.

Hau E, Bouaziz J, Lafaurie M, et al. 2016, Necrotizing Cellulitis With Multiple Abscesses on the Leg Caused by Serratia Marcescens. Cutis, 97(3): E8–E12.

Sisirak M, Hukic M. 2013, An Outbreak of Multidrug-Resistant Serratia Marcescens: The Importance of Continuous Monitoring of Nosocomial Infections. Acta Medica Academica, 42: 25–31.

Attman E, Korhonen P, Tammela O, et al. 2018, A Serratia Marcescens Outbreak in a Neonatal Intensive Care Unit Was Successfully Managed by Rapid Hospital Hygiene Interventions and Screening. Acta Paediatrica, 107(3): 425–429.

Vetter L, Schuepfer G, Kuster M, et al. 2016, A Hospital-Wide Outbreak of Serratia Marcescens and Ishikawa’s “Fishbone” Analysis to Support Outbreak Control. Quality Management in Health Care, 25: 1–7.

Us E, Kutlu H, Tekeli A, et al. 2017, Wound and Soft Tissue Infections of Serratia Marcescens in Patients Receiving Wound Care: A Health Care-Associated Outbreak. American Journal of Infection Control, 45(4): 443–447.

Mendes J, Casado A. 2022, Serratia Marcescens Outbreak in a COVID-19 Intensive Care Unit – Factors Facilitating Bacterial Cross-Contamination Between COVID-19 Patients. American Journal of Infection Control, 50(2): 223–225.

Lapenda J, Silva P, Vicalvi M, et al. 2015, Antimicrobial Activity of Prodigiosin Isolated From Serratia Marcescens UFPEDA 398. World Journal of Microbiology and Biotechnology, 31: 399–406.

Moradigaravand D, Boinett C, Martin V, et al. 2016, Independent Emergence of Multiple Multidrug-Resistant Serratia Marcescens Clones Within the United Kingdom and Ireland. Genome Research, 26: 1101–1109.

Tuon F, Cordova K, Dario T, et al. 2017, Klebsiella Pneumoniae Carbapenemase-Producing Serratia Marcescens Outbreak in a University Hospital. American Journal of Infection Control, 45(6): 700–702.

Moodley K, Peer A, Govind C. 2018, Pan Drug-Resistant Serratia Marcescens: An Emerging Threat. South African Medical Journal, 108: 12264.

Magiorakos A, Srinivasan A, Carey R, et al. 2012, Multidrug-Resistant, Extensively Drug-Resistant and Pandrug-Resistant Bacteria: An International Expert Proposal for Interim Standard Definitions for Acquired Resistance. Clinical Microbiology and Infection, 18(3): 268–281.

Clinical and Laboratory Standards Institute. 2017, Performance Standards for Antimicrobial Susceptibility Testing. CLSI M100-S23, Wayne, PA: CLSI.

Liou B, Duh R, Lin Y, et al. 2014, Multicenter Surveillance of Antimicrobial Resistance in Serratia Marcescens in Taiwan. Journal of Microbiology Immunology and Infection, 47: 387–393.

Simsek M. 2019, Determination of Antibiotic Resistance Rates of Serratia Marcescens Isolates Obtained From Various Clinical Specimens. Nigerian Journal of Clinical Practice, 22: 125–130.

Bielli A, Piazza A, Cento V, et al. 2020, In Vivo Acquisition and Risk of Inter-Species Spread of blaKPC-3 Plasmid From Klebsiella Pneumoniae to Serratia Marcescens in the Lower Respiratory Tract. Journal of Medical Microbiology, 69(1): 82–86.

Montagnani C, Cocchi P, Lega L, et al. 2015, Serratia Marcescens Outbreak in a Neonatal Intensive Care Unit: Role of Hand Hygiene Among External Consultants. BMC Infectious Diseases, 15: 11.

Wang X, Ge L, Li X. 2018, Distribution and Drug Resistance Analysis of Serratia Marcescens in Our Hospital During Five Years. Xinjiang Medical Journal, 48: 46–49.

Gonzalez G, Trevino-Rangel D, Campos C, et al. 2020, Surveillance of Antimicrobial Resistance in Serratia Marcescens in Mexico. The New Microbiologica, 43(1): 34–37.

Elsherbiny N, Ali I, Hassanein K, et al. 2018, Extended-Spectrum β-Lactamase-Producing Serratia Marcescens Causing Healthcare-Associated Infections in Assiut University Hospitals, Egypt. Journal of Global Antimicrobial Resistance, 13: 96–97.

Erenberg M, Yagel Y, Press F, et al. 2017, Chorioamnionitis Caused by Serratia Marcescens in a Healthy Pregnant Woman With Preterm Premature Rupture of Membranes: A Rare Case Report and Literature Review. European Journal of Obstetrics Gynecology and Reproductive Biology, 211: 227–230.

Ingo S, Sonja B, Sherwood K, et al. 2003, Natural Antimicrobial Susceptibilities of Strains of Unusual Serratia Species: S. Ficaria, S. Fonticola, S. Odorifera, S. Plymuthica and S. Rubidaea. Journal of Antimicrobial Chemotherapy, 51: 865–885.

Li J, Hu Z, Wang F, et al. 2016, Resistance Surveillance of Proteus, Serratia, Citrobacter, Morganella, and Providencia spp. in China: Results From the CHINET Antimicrobial Resistance Surveillance Program, 2005–2014. Chinese Journal of Infection and Chemotherapy, 16(3): 10.

Zhang Y, Zhou W, Li J, et al. 2021, Phenotypic Analysis of 53 Strains of Serratia Marcescens Resistant to Carbapenems. Journal of Clinical Transfusion and Laboratory Medicine, 23(1): 87–90.

Moodley K, Peer A, Govind C. 2018, Pan Drug-Resistant Serratia Marcescens: An Emerging Threat. South African Medical Journal, 108: 12264.